{"id":16404,"date":"2024-12-03T14:21:27","date_gmt":"2024-12-03T06:21:27","guid":{"rendered":"https:\/\/flcube.com\/?p=16404"},"modified":"2024-12-03T14:21:31","modified_gmt":"2024-12-03T06:21:31","slug":"ucb-partners-with-bioray-biopharmaceutical-for-bimzelx-commercial-promotion-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=16404","title":{"rendered":"UCB Partners with BioRay Biopharmaceutical for Bimzelx Commercial Promotion in China"},"content":{"rendered":"\n

Belgium based UCB (EBR: UCB<\/a>) is fulfilling its commitment to enhance attention to innovative products and local partnerships in the Chinese market by signing an agreement with Zhejiang based BioRay Pharmaceutical Co., Ltd. for the commercial promotion of its Bimzelx (bimekizumab) in China. The financial details of the deal have not been disclosed. This partnership follows UCB’s recent divestment of its mature neurology and allergy business in China to CBC Group and Mubadala Investment Company, as reported by Fineline Info & Tech<\/a>.<\/p>\n\n\n\n

Bimzelx: A Targeted Antibody for Psoriasis and Related Conditions<\/strong>
Bimzelx is an interleukin 17A (IL-17A) and IL-17F targeted antibody that was first approved in the United States in October of last year for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It is the world’s fourth IL-17-targeted drug. Since then, Bimzelx has earned approval in the U.S. for three additional indications: adults with active psoriatic arthritis (PsA), adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation, and adults with active ankylosing spondylitis (AS).<\/p>\n\n\n\n

Bimzelx’s Registration and Approval in China<\/strong>
Bimzelx is also registered in China, having received approval to treat adult patients with active AS who have responded inadequately or are intolerant to conventional therapy in July this year. This registration and approval mark a significant step in expanding access to this innovative treatment for patients in China.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Belgium based UCB (EBR: UCB) is fulfilling its commitment to enhance attention to innovative products…<\/p>\n","protected":false},"author":1,"featured_media":16410,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[65,2575,2015,131],"class_list":["post-16404","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-auto-immune","tag-bioray-pharmaceutical","tag-ebr-ucb","tag-ucb"],"yoast_head":"\nUCB Partners with BioRay Biopharmaceutical for Bimzelx Commercial Promotion in China - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Belgium based UCB (EBR: UCB) is fulfilling its commitment to enhance attention to innovative products and local partnerships in the Chinese market by signing an agreement with Zhejiang based BioRay Biopharmaceutical for the commercial promotion of its Bimzelx (bimekizumab) in China. The financial details of the deal have not been disclosed. This partnership follows UCB's recent divestment of its mature neurology and allergy business in China to CBC Group and Mubadala Investment Company, as reported by Fineline Info & Tech.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=16404\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"UCB Partners with BioRay Biopharmaceutical for Bimzelx Commercial Promotion in China\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=16404\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-03T06:21:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-03T06:21:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0301.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"537\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16404#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16404\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"UCB Partners with BioRay Biopharmaceutical for Bimzelx Commercial Promotion in China\",\"datePublished\":\"2024-12-03T06:21:27+00:00\",\"dateModified\":\"2024-12-03T06:21:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16404\"},\"wordCount\":255,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16404#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/0301.png\",\"keywords\":[\"Auto-immune\",\"BioRay Pharmaceutical\",\"EBR: UCB\",\"UCB\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=16404#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16404\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=16404\",\"name\":\"UCB Partners with BioRay Biopharmaceutical for Bimzelx Commercial Promotion in China - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16404#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16404#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/0301.png\",\"datePublished\":\"2024-12-03T06:21:27+00:00\",\"dateModified\":\"2024-12-03T06:21:31+00:00\",\"description\":\"Belgium based UCB (EBR: UCB) is fulfilling its commitment to enhance attention to innovative products and local partnerships in the Chinese market by signing an agreement with Zhejiang based BioRay Biopharmaceutical for the commercial promotion of its Bimzelx (bimekizumab) in China. The financial details of the deal have not been disclosed. This partnership follows UCB's recent divestment of its mature neurology and allergy business in China to CBC Group and Mubadala Investment Company, as reported by Fineline Info & Tech.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16404#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=16404\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16404#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/0301.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/0301.png\",\"width\":1080,\"height\":537,\"caption\":\"UCB Partners with BioRay Biopharmaceutical for Bimzelx Commercial Promotion in China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16404#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"UCB Partners with BioRay Biopharmaceutical for Bimzelx Commercial Promotion in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"UCB Partners with BioRay Biopharmaceutical for Bimzelx Commercial Promotion in China - Insight, China's Pharmaceutical Industry","description":"Belgium based UCB (EBR: UCB) is fulfilling its commitment to enhance attention to innovative products and local partnerships in the Chinese market by signing an agreement with Zhejiang based BioRay Biopharmaceutical for the commercial promotion of its Bimzelx (bimekizumab) in China. The financial details of the deal have not been disclosed. This partnership follows UCB's recent divestment of its mature neurology and allergy business in China to CBC Group and Mubadala Investment Company, as reported by Fineline Info & Tech.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=16404","og_locale":"en_US","og_type":"article","og_title":"UCB Partners with BioRay Biopharmaceutical for Bimzelx Commercial Promotion in China","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=16404","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-12-03T06:21:27+00:00","article_modified_time":"2024-12-03T06:21:31+00:00","og_image":[{"width":1080,"height":537,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0301.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=16404#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=16404"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"UCB Partners with BioRay Biopharmaceutical for Bimzelx Commercial Promotion in China","datePublished":"2024-12-03T06:21:27+00:00","dateModified":"2024-12-03T06:21:31+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=16404"},"wordCount":255,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=16404#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0301.png","keywords":["Auto-immune","BioRay Pharmaceutical","EBR: UCB","UCB"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=16404#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=16404","url":"https:\/\/flcube.com\/?p=16404","name":"UCB Partners with BioRay Biopharmaceutical for Bimzelx Commercial Promotion in China - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=16404#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=16404#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0301.png","datePublished":"2024-12-03T06:21:27+00:00","dateModified":"2024-12-03T06:21:31+00:00","description":"Belgium based UCB (EBR: UCB) is fulfilling its commitment to enhance attention to innovative products and local partnerships in the Chinese market by signing an agreement with Zhejiang based BioRay Biopharmaceutical for the commercial promotion of its Bimzelx (bimekizumab) in China. The financial details of the deal have not been disclosed. This partnership follows UCB's recent divestment of its mature neurology and allergy business in China to CBC Group and Mubadala Investment Company, as reported by Fineline Info & Tech.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=16404#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=16404"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=16404#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0301.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0301.png","width":1080,"height":537,"caption":"UCB Partners with BioRay Biopharmaceutical for Bimzelx Commercial Promotion in China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=16404#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"UCB Partners with BioRay Biopharmaceutical for Bimzelx Commercial Promotion in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0301.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/16404","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=16404"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/16404\/revisions"}],"predecessor-version":[{"id":16411,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/16404\/revisions\/16411"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/16410"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=16404"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=16404"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=16404"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}